DB:0FY

Stock Analysis Report

Executive Summary

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Equillium's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0FY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.5%

0FY

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-29.6%

0FY

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 0FY underperformed the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 0FY underperformed the German Market which returned 2.9% over the past year.


Shareholder returns

0FYIndustryMarket
7 Day3.5%-11.1%-9.1%
30 Day6.7%-12.8%-7.2%
90 Day63.7%-9.6%-6.5%
1 Year-29.6%-29.6%-2.7%-2.9%6.1%2.9%
3 Yearn/a25.8%24.4%3.5%-5.6%
5 Yearn/a1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Equillium's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Equillium undervalued compared to its fair value and its price relative to the market?

1.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0FY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0FY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0FY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0FY is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0FY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0FY is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Equillium forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-1.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0FY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0FY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0FY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 0FY's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 0FY's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0FY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Equillium performed over the past 5 years?

-134.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 0FY is currently unprofitable.

Growing Profit Margin: 0FY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 0FY's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 0FY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0FY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 0FY has a negative Return on Equity (-47.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Equillium's financial position?


Financial Position Analysis

Short Term Liabilities: 0FY's short term assets ($62.9M) exceed its short term liabilities ($4.3M).

Long Term Liabilities: 0FY's short term assets ($62.9M) exceed its long term liabilities ($9.8M).


Debt to Equity History and Analysis

Debt Level: 0FY's debt to equity ratio (19.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 0FY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 0FY has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0FY's debt is covered by short term assets (assets are 6.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0FY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 0FY has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -107% each year.


Next Steps

Dividend

What is Equillium's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0FY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0FY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0FY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0FY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0FY's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Bruce Steel (53yo)

0.08yrs

Tenure

Mr. Bruce D. Steel, CFA has been Chief Executive Officer of Equillium, Inc. since January 1, 2020. He has been a Managing Director at BioMed Ventures LP since September 2010. Mr. Steel serves as President  ...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Bradbury
Executive Chairman2.9yrsUS$315.00k4.27% $3.6m
Stephen Connelly
Chief Scientific Officer & Director2.9yrsUS$373.75k7.44% $6.3m
Krishna Polu
Executive Vice President Research & Development1.5yrsUS$2.57mno data
Bruce Steel
Co-Founder0.08yrsno data21.36% $18.0m
Jason Keyes
Chief Financial Officer1.9yrsno data0.75% $631.4k
Christine Zedelmayer
Senior VP & COO0yrsno data0.41% $342.6k
Joel Rothman
Senior Vice President of Development Operations0yrsno datano data

1.5yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 0FY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Daniel Bradbury
Executive Chairman2.9yrsUS$315.00k4.27% $3.6m
Stephen Connelly
Chief Scientific Officer & Director2.9yrsUS$373.75k7.44% $6.3m
Bruce Steel
Co-Founder0.08yrsno data21.36% $18.0m
Martha Demski
Independent Director1.4yrsUS$255.30k0.14% $115.1k
Bala Manian
Independent Director2.8yrsUS$13.52k0.14% $115.1k
Mark Pruzanski
Independent Director1.4yrsUS$251.77k0.14% $115.1k
Vijay Kuchroo
Member of Scientific & Clinical Advisory Board0yrsno datano data
Charles McDermott
Independent Director1.4yrsUS$254.29k0.14% $115.1k
Fred Ramsdell
Member of Scientific & Clinical Advisory Board0yrsno datano data
Pradip Nair
Member of Scientific & Clinical Advisory Board0yrsno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 0FY's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.7%.


Top Shareholders

Company Information

Equillium, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Equillium, Inc.
  • Ticker: 0FY
  • Exchange: DB
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$92.268m
  • Listing Market Cap: US$84.065m
  • Shares outstanding: 17.38m
  • Website: https://www.equilliumbio.com

Number of Employees


Location

  • Equillium, Inc.
  • 2223 Avenida De La Playa
  • Suite 105
  • San Diego
  • California
  • 92037
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EQNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2018
0FYDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2018

Biography

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 00:10
End of Day Share Price2020/02/27 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.